BCACP Cardiovascular Risk Reduction 3

Question 1

A patient taking rosuvastatin 40 mg develops muscle pain with a CK level 12 times the upper limit of normal. What is the most appropriate action?

Accepted Answer

Discontinue rosuvastatin immediately

Answer

CK >10x ULN with symptoms indicates myopathy requiring immediate statin discontinuation to prevent progression to rhabdomyolysis.

Question 2

Which non-HDL cholesterol target is recommended for very high-risk cardiovascular patients per current guidelines?

Accepted Answer

<100 mg/dL

Answer

Non-HDL-C goal for very high-risk patients is <100 mg/dL, which corresponds to an LDL-C goal of <70 mg/dL plus 30 mg/dL.

Question 3

A patient with ASCVD on maximum-tolerated statin therapy has LDL-C of 95 mg/dL. Which add-on therapy has outcomes data showing reduced CV events?

Accepted Answer

Ezetimibe

Answer

The IMPROVE-IT trial demonstrated that adding ezetimibe to statin therapy reduced major cardiovascular events in high-risk patients.

Question 4

In the SPRINT trial, what systolic blood pressure target was associated with reduced cardiovascular events compared to standard control?

Accepted Answer

<120 mmHg

Answer

SPRINT showed that intensive SBP target of <120 mmHg reduced CV events and all-cause mortality compared to <140 mmHg in high-risk non-diabetic patients.

Question 5

Which smoking cessation pharmacotherapy is CONTRAINDICATED in a patient with a history of seizure disorder?

Accepted Answer

Bupropion

Answer

Bupropion lowers the seizure threshold and is contraindicated in patients with seizure disorders or eating disorders.

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP - Board Certified Ambulatory Care Pharmacist Exam Practice Test

BCACP Cardiovascular Risk Reduction 3